Management of varicella zoster infections in immunocompetent hosts.
Varicella in otherwise healthy children usually requires no antiviral treatment. In severe cases, however, such as are seen in neonates and adults, treatment must be given. Anecdotal evidence suggests the efficacy of intravenous acyclovir in such patients. Herpes zoster in immunocompetent patients may be severe enough to warrant antiviral therapy, particularly in elderly patients. Both idoxuridine and acyclovir have been investigated in placebo-controlled double-blind studies. Due to its low toxicity, ease of administration, and the possibility of systemic administration, acyclovir has largely replaced older antivirals in the management of herpes zoster in the normal host. Recent studies have shown the efficacy of oral acyclovir. In addition, oral acyclovir may prevent the ocular complications of ophthalmic zoster. When acyclovir is given, it should be administered as early as possible, preferably no later than four days after the onset of the rash. The combination of acyclovir and prednisolone for the prevention of post-herpetic neuralgia has not proved effective.
D000212:Acyclovir / Q000627:therapeutic use*; D002644:Chickenpox / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006562:Herpes Zoster / Q000188:drug therapy*; D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use; D007109:Immunity; D009437:Neuralgia / Q000517:prevention & control; D011239:Prednisolone / Q000627:therapeutic use
D011239:Prednisolone; D007065:Idoxuridine; D000212:Acyclovir